Results 11 to 20 of about 94,635 (266)

Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients

Arthritis Research & Therapy, 2018
Background The aim of this study was to assess the outcomes of remission induction in patients with IgG4-related disease (IgG4-RD) in our cohort, and to investigate the characteristics, prognosis, and risk factors in the patients failed of remission ...
Liwen Wang, Panpan Zhang, Mu Wang, Ruie Feng, Yamin Lai, Linyi Peng, Yunyun Fei, Xuan Zhang, Yan Zhao, Xiaofeng Zeng, Fengchun Zhang, Wen Zhang   +11 more
doaj   +1 more source

Glutamine for induction of remission in Crohn's disease [PDF]

Cochrane Database of Systematic Reviews, 2016
Crohn's disease is a chronic relapsing condition of the alimentary tract with a high morbidity secondary to bowel inflammation. Glutamine plays a key role in maintaining the integrity of the intestinal mucosa and has been shown to reduce inflammation and disease activity in experimental models of Crohn's disease.To evaluate the efficacy and safety of ...
Akobeng, Anthony, Elawad, M, Gordon, Morris   +2 more
openaire   +2 more sources

Etrolizumab for induction of remission in ulcerative colitis

Cochrane Database of Systematic Reviews, 2015
Etrolizumab (rhuMAb beta7) is an anti-integrin that selectively targets the β7 subunits of the α4β7 and αEβ7 integrins, which are involved in the pathogenesis of ulcerative colitis.The objectives of this review were to assess the efficacy and safety of etrolizumab for induction of remission in ulcerative colitis.We searched PubMed, MEDLINE, EMBASE, and
Greg, Rosenfeld, Claire E, Parker, John K, MacDonald, Brian, Bressler   +3 more
openaire   +3 more sources

Probiotics for induction of remission in Crohn's disease [PDF]

Cochrane Database of Systematic Reviews, 2008
Crohn's disease has a high morbidity and there is no known cure. Current treatments have multiple side effects and an effective treatment with minimal side effects is desired. Probiotics have been proposed as such a treatment but their efficacy is undetermined.
Andrew D, Butterworth, Adrian G, Thomas, Anthony Kwaku, Akobeng   +2 more
openaire   +2 more sources

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation

Haematologica, 2016
Up to 30% of adults with acute myeloid leukemia fail to achieve a complete remission after induction chemotherapy - termed primary refractory acute myeloid leukemia.
Paul Ferguson, Robert K. Hills, Angela Grech, Sophie Betteridge, Lars Kjeldsen, Michael Dennis, Paresh Vyas, Anthony H. Goldstone, Donald Milligan, Richard E. Clark, Nigel H. Russell, Charles Craddock   +11 more
doaj   +1 more source

Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

Arthritis Research & Therapy, 2018
Background The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction ...
Josef S. Smolen, Annette Szumski, Andrew S. Koenig, Thomas V. Jones, Lisa Marshall   +4 more
doaj   +1 more source

End of induction treatment outcomes with a novel cyclophosphamide-based regimen for severe lupus nephritis: Single-center experience from South India

Indian Journal of Rheumatology, 2020
Background: Cyclophosphamide is commonly used along with pulse steroids for induction immunosuppression treatment of severe forms of lupus nephritis (LN).
V Jayaprakash, T Dineshkumar, J Dhanapriya, D Rajasekar, R Sakthirajan, T Balasubramaniyan, Anila A Kurien, N Gopalakrishnan   +7 more
doaj   +1 more source

Successful treatment of idiopathic retroperitoneal fibrosis with combined immunosuppressive therapy [PDF]

Vojnosanitetski Pregled, 2019
Background/Aim. Idiopathic retroperitoneal fibrosis (IRF) is characterized by the fibroinflammatory periaortic tissue that affects the ureters, causing obstructive nephropathy and variable impairment of renal function.
Obrenčević Katarina, Petrović Dejan, Aleksić Predrag, Petrović Marijana, Rančić Nemanja, Jovanović Dragan, Nikolić Bojan, Mijušković Mirjana, Vavić Neven, Ignjatović Ljiljana, Maksić Đoko   +10 more
doaj   +1 more source

Adalimumab for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews, 2017
Adalimumab is an IgG1 monoclonal antibody that targets and blocks tumor necrosis factor-alpha, a pro-inflammatory cytokine involved in the pathogenesis of Crohn's disease (CD). A significant proportion of people with CD fail conventional therapy or therapy with biologics or develop significant adverse events.
Mohamad, Abbass, Jeremy, Cepek, Claire E, Parker, Tran M, Nguyen, John K, MacDonald, Brian G, Feagan, Reena, Khanna, Vipul, Jairath   +7 more
openaire   +4 more sources

Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis

The Saudi Journal of Gastroenterology, 2017
Background/Aims: Treatment of refractory ulcerative colitis (UC) is a clinical challenge, and after biological therapy, monitoring clinical and endoscopic responses is fundamental.
Elham A Hassan, Haidi K Ramadan, Ali A Ismael, Khaled F Mohamed, Madiha M El-Attar, Ihab Alhelali   +5 more
doaj   +1 more source